NAD+ 500mg – 200mg/mL
NAD+ 500mg – 200mg/mL is used in prescriber-directed longevity, peptide, antioxidant, or skin-longevity protocols. Published evidence varies substantially by ingredient, so the page avoids unsupported disease-treatment claims.
NAD⁺ 500 mg at 200 mg/mL is a moderate-to-high-dose, concentrated intravenous compounded NAD⁺ infusion formulation containing the full 500 mg dose in only 2.5 mL of concentrate, which must be diluted before IV administration. This concentration is frequently used for maintenance IV infusion sessions (weekly or bi-weekly) in patients who have completed an intensive repletion course and are transitioning to a lower-maintenance dosing strategy. Genesis Compounding prepares this as a prescriber-directed, patient-specific 503A compounded preparation; it is not FDA-approved.
| Active Ingredient | Pharmacologic Role |
|---|---|
| NAD⁺ 500 mg (200 mg/mL) | Endogenous redox coenzyme for systemic NAD⁺ repletion at a maintenance or moderate-dose infusion level; supports sirtuin activation, PARP-mediated DNA repair, and mitochondrial metabolic function. |
Intravenous infusion (dilute before use): Dilute in normal saline or D5W per pharmacy instructions. Infuse via peripheral IV over 1–2 hours at a controlled rate. The 500 mg dose at a moderate infusion rate is generally well tolerated by patients who have acclimated to NAD⁺ therapy. Monitor for rate-dependent adverse effects and reduce infusion rate if flushing, nausea, or discomfort occurs.
All dosing is prescriber-determined.
- Weekly or bi-weekly maintenance infusions of 500 mg following an intensive induction course.
- May also be prescribed as a standalone dose for patients with moderate NAD⁺ depletion.
Identical to general NAD⁺ mechanism (ID 154). The 500 mg maintenance dose sustains cellular NAD⁺ pools to maintain sirtuin and PARP activity between intensive infusion courses.
Maintenance infusion programming after initial intensive repletion; weekly wellness protocols for age-related NAD⁺ decline, post-viral fatigue, and metabolic optimization. All applications are off-label and investigational.
See general NAD⁺ safety (ID 154). At 500 mg, infusion-related effects (flushing, nausea, cramping) are less pronounced than at 1000–1200 mg but remain rate-dependent. Monitor appropriately during infusion.
Contraindications:
- Hypersensitivity to NAD⁺ or nicotinamide
Common Side Effects: Flushing, mild nausea, headache (rate-dependent and reversible).
Refrigerate at 2–8°C, protected from light. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding. Discard any unused concentrate after the beyond-use date.
Is 500 mg a lower or higher dose compared to the other NAD⁺ formulations?
500 mg is a moderate dose, lower than the 1000 mg and 1200 mg infusion formulations. It is commonly used as a maintenance dose between intensive infusion sessions, balancing efficacy with tolerability.
How long does the infusion take?
Typically 1–2 hours when infused at a controlled rate to minimize discomfort.
Is this FDA-approved?
No. This is a prescriber-directed, patient-specific 503A compounded preparation.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.